Biosimilars through Physician’s Lens – Strategic Intelligence

All the vital news, analysis, and commentary curated by our industry experts.

$1950

Buy Report

Published: March 31, 2025 Report Code: GDHCHT574-TH

Report Overview
Key Players
Table of Contents

Since their introduction within the past few decades, biosimilars outrivaled biologics in reducing treatment costs and improving access to therapies for chronic conditions such as cancer, rheumatoid arthritis (RA), and diabetes. Nevertheless, while biosimilars are increasingly recognized for their clinical and economic benefits, their uptake has been slower than anticipated in some markets. The physician’s role in shaping the future of biosimilar use is undeniable, given their influence on prescribing practices and patient trust. In this report, GlobalData examines biosimilar use, focusing on physician perceptions. The report provides insights into biosimilar uptake, substitution patterns, and use across the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan, and China).

– Biosimilar uptake varies across therapeutic areas and regions, driven by factors such as regulatory policies and market dynamics.
– The global biosimilar market is forecast to reach $24.75 billion in sales by 2030 with the US driving the most sales.
– Across all markets surveyed, healthcare providers (HCPs) confirmed that their biosimilar prescriptions are going to increase in the next five years.
– Physicians generally support substituting branded biologics with biosimilars.
– If cost was not the main factor, close to 40% of physicians would prefer to use branded biologics for their patients.
– Despite market differences, most physicians agreed that patients should have an option to choose between biologics and their biosimilars.
– China has strong potential in the biosimilars market but may face tough global competition.
– The US’s IRA may have limited impact on biosimilars, while the BIOSECURE Act may increase their prices due to manufacturing and supply chain disruptions.

Scope

– Physicians' attitude and opinions on biosimilar prescription, substitution, and interchangeability

– Past and future uptakes of biosimilars

– Barriers to biosimilar uptake

– Cost consideration of biosimilar prescription

– Patients' preference on branded biologics and biosimilars

– Differences on biosimilar across markets

Reasons to Buy

– Assess healthcare professionals’ attitude towards biosimilar prescription.

– Better understand the barriers to biosimilar uptake.

– Capture physicians’ opinions on substitution and interchangeability.

– Better understand patients’ preferences.

– Assess past and future biosimilars uptake.

– Gain a better understanding of cost consideration when prescribing drugs.

– Explore the differences across markets.

3SBio Inc
AbbVie Inc
Accord Healthcare Ltd
Alphamab Oncology
Alteogen Inc
Altos Biologics Co Ltd
Alvotech SA
Amgen Inc
AskGene Pharma Inc
BeiGene Ltd
BioAtla Inc
Biocon Biologics Ltd
Biogen Inc
Biora Therapeutics Inc
Bio-Thera Solutions Ltd
Boehringer Ingelheim
Bora Pharmaceuticals Co Ltd
Celltrion Inc
Coherus BioSciences Inc
CSL Behring
CSPC Pharmaceutical Group Ltd
Dong-A Socio Group
Eris Lifesciences Ltd
Formycon AG
Fresenius Kabi AG
Fuji Pharma Co Ltd
Gedeon Richter Plc
Genor BioPharma Co Ltd
Hong Kong King-Friend Pharmaceutical Co Ltd
Huons Co Ltd
Innovent Biologics Inc
Intas Pharmaceuticals Ltd
Janssen
JCR Pharmaceuticals Co Ltd
Jiangsu Aosaikang Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kissei Pharmaceutical Co Ltd
Kyowa Kirin Co Ltd
Levim Lifetech Pvt Ltd
Luye Pharma Group Ltd
Meitheal Pharmaceuticals Inc
Mochida Pharmaceutical Co Ltd
Mylan Inc
Novartis AG
Ocumension Therapeutics Co Ltd
Organon
Outlook Therapeutics Inc
Pangen Biotech Inc
Pfizer
Rani Therapeutics LLC
Roche
Sam Chun Dang Pharm Co Ltd
Samsung Bioepis Co Ltd
Samsung Biologics Co Ltd
Sandoz
Sanofi
Shanghai Henlius Biotech Inc
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Sino Biopharmaceutical Ltd
Strides Pharma Science Ltd
Tanvex BioPharma Inc
Teva Pharmaceutical Industries Ltd
Torrent Investments Pvt Ltd
Torrent Pharmaceuticals Ltd
Viatris
Wockhardt Ltd
Xbrane Biopharma AB

1. Executive Summary

2. Study Design

3. Biosimilars Overview

4. Biosimilars – Current and Future Uptake

5. Biosimilars Versus Biologics Use

6. Physician Attitude Towards Biosimilars

7. Deal-Making Activities in the Biosimilars Space

8. Future Considerations

9. Summary of Key Findings

10. Appendix

11. About the Authors

12. Contact Us

Biosimilars through Physician’s Lens – Strategic Intelligence thematic reports

Currency USD

Single User

$1,950

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Biosimilar reports

Pharmaceuticals

New

Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…

Pharmaceuticals

New

Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035

Pharmaceuticals

New

Overweight and Obesity: Epidemiology Report and Forecast to 2035

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Biosimilars through Physician’s Lens – Strategic Intelligence in real time.

Access a live Biosimilars through Physician’s Lens – Strategic Intelligence dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Biosimilars through Physician’s Lens – Strategic Intelligence

Scope

Reasons to Buy

Table of Contents

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports